Barrett's esophagus

Gastroenterology

Volumn 122, Issue 6, 2002, Pages 1569-1591

  Falk, Gary W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOSCOPY; ESOPHAGUS CARCINOMA; ESOPHAGUS INJURY; GASTROESOPHAGEAL REFLUX; HUMAN; INCIDENCE; INTESTINE METAPLASIA; LOWER ESOPHAGUS SPHINCTER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0036091028     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.33427     Document Type: Article

References (226)

1. A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting
2. Barrett's esophagus: Its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux
3. Barrett's esophagus: A prevalent occult complication of gastroesophageal reflux disease
4. Prevalence of columnar-lined (Barrett's esophagus)
5. Barrett's esophagus: Age, prevalence, and extent of columnar epithelium
6. Barrett's esophagus: Results of a multicenter survey
7. Heartburn requiring frequent antacid use may indicate significant illness
8. Prevalence of metaplasia at the gastro-oesophageal junction
9. Barrett's esophagus: The long and the short of it
10. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus
11. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data
12. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota
13. Prevalence of Barrett's esophagus in Hispanics is similar to Caucasians
14. Erosive esophagitis and Barrett's esophagus in Taiwan. A higher frequency than expected
15. The cohort effect and Helicobacter pylori
16. Opposing time trends of peptic ulcer and reflux disease
17. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus
18. Risk factors for Barrett's esophagus in community-based practice
19. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
20. The prevalence of intestinal metaplasia in patients with and without peptic strictures
21. The prevalence of Barrett's esophagus in patients with chronic peptic esophageal strictures
22. Esophageal acid sensitivity in Barrett's esophagus
23. Reduced chemoreceptor sensitivity in patients with Barrett's esophagus may be related to age and not to the presence of Barrett's epithelium
24. Familial Barrett's esophagus associated with adenocarcinoma
25. Barrett's esophagus: An acquired condition with genetic predisposition
26. Familial Barrett's esophagus and adenocarcinoma of the gastroesophageal junction
27. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma
28. Barrett's esophagus: Congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog
29. Experimental columnar metaplasia in the canine oesophagus
30. 24 Hour ambulatory oesophageal pH monitoring in uncomplicated Barrett's oesophagus
31. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present
32. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure
33. Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis?
34. Barrett's esophagus: Prevalence and size of hiatal hernia
35. Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls
36. Duodenogastroesophageal reflux: Relationship to pH and importance in Barrett's esophagus
37. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease
38. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus
39. Correlation of oesophageal acid exposure with Barrett's oesophagus length
40. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus
41. Distribution of cytokeratin markers in Barrett's columnar epithelium
42. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus
43. The quality of care in Barrett's esophagus: Endoscopist and pathologist practices
44. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice
45. Short segment Barrett's esophagus: The need for standardization of the definition and of endoscopic criteria
46. The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: Implications for patient treatment and preventive strategies in Barrett's esophagus
47. Specialized columnar epithelium of the esophagogastric junction: Prevalence and associations
48. Intestinal metaplasia at the gastroesophageal junction: Helicobacter pylori gastritis or gastrooesophageal reflux disease?
49. Short segments of Barrett's epithelium and intestinal metaplasia in normal appearing oesophagogastric junctions: The same or two different entities
50. Intestinal metaplasia at the squamocolumnar junction in patients attending for diagnostic gastroscopy
51. Inflammation and intestinal metaplasia of the gastric cardia: The role of gastroesophageal reflux and H. pylori infection
52. Characteristics of intestinal metaplasia of the gastric cardia
53. Dysplasia in short-segment Barrett's esophagus: A prospective 3-year follow-up
54. Adenocarcinomas arising in tongues or short segments of Barrett's esophagus
55. Curable cancer in a short segment Barrett's esophagus
56. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: Comparisons with traditional long segment Barrett's esophagus
57. Effect of segment length on risk for neoplastic progression in patients with Barrett's esophagus
58. Relative risk of dysplasia for patients with intestinal metaplasia in the distal esophagus and in the gastric cardia
59. Dysplastic gastroesophageal junction nodules: A precursor to junctional adenocarcinoma
60. Longterm follow-up of intestinal metaplasia of the gastric cardia
61. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy
62. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus
63. Methylene blue chromoendoscopy for detection of short segment Barrett's esophagus
64. Comparison of methylene-blue directed biopsies and conventional biopsies in the detection of intestinal metaplasia in Barrett's esophagus: A preliminary study
65. Detection of a shared colon epitope on Barrett epithelium by a novel monoclonal antibody
66. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction
67. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach
68. Cytokeratin immunoreactivity patterns in the diagnosis of short segment Barrett's esophagus
69. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens
70. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus
71. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
72. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
73. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males
74. Gastroesophageal reflux disease, use of H2 receptor antagonists and risk of esophageal and gastric cancer
75. Association between body mass and adenocarcinoma of the esophagus
76. Body mass index and risk of adenocarcinoma of the esophagus and gastric cardia
77. A case-control study of oesophageal adenocarcinoma in women: A preventable disease
78. Adenocarcinoma of the esophagus: Role of obesity and diet
79. Increasing incidence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991
80. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia
81. Association between medications that relax the lower esophageal sphincter and esophageal adenocarcinoma
82. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux
83. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia
84. + strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma
85. The seroprevalence of cagA positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease
86. The rising trend in oesophageal adenocarcinoma and gastric cardia
87. Increasing incidence of adenocarcinoma of the esophagus and the esophagogastric junction
88. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's esophagus
89. Barrett's esophagus: Development of dysplasia and adenocarcinoma
90. Only patients with dysplasia progress to adenocarcinoma in Barrett's esophagus
91. Length of Barrett's oesophagus: An important factor in the development of dysplasia and adenocarcinoma
92. The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years
93. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's esophagus registry
94. Life expectancy and cancer risk in patients with Barrett's esophagus: A prospective controlled investigation
95. Barrett's oesophagus: Results from a 13-year surveillance programme
96. Is there a publication bias in the reporting of cancer risk in Barrett's esophagus?
97. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus
98. Barrett's esophagus: Cell cycle abnormalities in advancing stages of neoplastic progression
99. Epithelial proliferation of Barrett's esophagus by proliferating cell nuclear antigen immunolocalization
100. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus
101. Barrett's esophagus: Ordering the events that lead to cancer
102. Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus
103. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region
104. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus
105. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort
106. Chromosomal rearrangements in Barrett's esophagus. A premalignant lesion of esophageal adenocarcinoma
107. Progression to cancer in Barrett's esophagus is associated with genomic instability
108. Cyclooxygenase expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence
109. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure
110. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells
111. The changing epidemiology of esophageal cancer
112. Superficial esophageal carcinoma
113. Determinants of survival following the diagnosis of esophageal adenocarcinoma
114. Adenocarcinoma of the esophagus and Barrett's esophagus: A population-based study
115. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota
116. Unsedated small-caliber esophagogastroduodenoscopy (EGD) versus conventional EGD: A comparative study
117. A low-cost fiber-optic instrument to colorimetrically detect patients with Barrett's esophagus for early detection of esophageal adenocarcinoma
118. Surveillance of Barrett's esophagus for dysplasia and cancer with balloon cytology
119. Screening for high-grade dysplasia in gastroesophageal reflux disease: Is it cost effective?
120. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux
121. Endoscopic surveillance of Barrett's esophagus. Does it help?
122. Impact of endoscopic biopsy surveillance of Barrett's esophagus on pathological stage and clinical outcome of Barrett's carcinoma
123. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients
124. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk
125. Endoscopic surveillance of Barrett's esophagus: A cost-effectiveness comparison with mammographic surveillance for breast cancer
126. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus
127. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: Observational study
128. Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: A reaffirmation
129. Observer variation in the diagnosis of dysplasia in Barrett's esophagus
130. Endoscopic biopsy technique for acquiring larger mucosal samples
131. Barrett's esophagus, high-grade dysplasia and early adenocarcinoma
132. An endoscopic biopsy protocol can differentiate highgrade dysplasia from early adenocarcinoma in Barrett's esophagus
133. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia
134. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia
135. Practice patterns for surveillance of Barrett's esophagus in the United States
136. High-grade dysplasia in Barrett's esophagus: Surveillance or operation?
137. Management of Barrett's esophagus: A national study of practice patterns and their cost implications
138. Surveillance of Barrett's esophagus: A need for guidelines
139. Endoscopic biopsies and cytologic brushings of the esophagus are diagnostically complementary
140. Detection of p53 nuclear protein accumulation in brushings and biopsies of Barrett's esophagus
141. Diagnostic value of cytopathology in Barrett esophagus and associated carcinoma
142. A comparative cytopathologic, histologic study of atypia, dysplasia, and adenocarcinoma in Barrett's esophagus
143. Brush cytology in the diagnosis of neoplasia in Barrett's esophagus
144. Usefulness of cytopathology and histology in the evaluation of Barrett's esophagus in a community hospital
145. Methylene-blue directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus
146. Sky blue or murky waters: The diagnostic utility of methylene blue
147. Methylene blue staining: Is it really useful?
148. Fluorescence, reflectance, and lightscattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus
149. Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus
150. Endoscopic detection of dysplasia in patients with Barrett's esophagus using light-scattering spectroscopy
151. Diagnosis of specialized intestinal metaplasia by optical coherence tomography
152. Autofluorescence endoscopy: Feasibility of detection of GI neoplasms unapparent to white light endoscopy with an evolving technology
153. Accuracy of fluorescence imaging of dysplasia in Barrett's esophagus
154. Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolevulinic acid sensitization
155. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma
156. Risk factors for the development of an adenocarcinoma in the columnar-lined esophagus
157. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression
158. P53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: Immunohistochemical marker predictive of progression
159. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma
160. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets
161. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia
162. Long-term follow-up of Barrett's high-grade dysplasia
163. Interobserver variation in Barrett's related high-grade dysplasia and superficial adenocarcinoma: Can it be improved using uniform pathologic criteria?
164. P53 and neoplastic progression in Barrett's esophagus
165. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: A follow-up study
166. Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma
167. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression
168. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients
169. Endoscopic regression of Barrett's esophagus during omeprazole treatment: A randomized double blind study
170. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus
171. Long term continuous omeprazole treatment of patients with Barrett's oesophagus
172. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus
173. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole
174. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus
175. 24-H pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors
176. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: Results of 5 years of continuous therapy
177. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy
178. Squamous islands in Barrett's esophagus: What lies underneath?
179. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus
180. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus
181. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor
182. Maximal acid reflux control for Barrett's oesophagus: Feasible and effective
183. H2RAs do not provide sustained suppression of nocturnal acid breakthrough
184. Conservative treatment versus antireflux surgery in Barrett's oesophagus: Long-term results of a prospective study
185. Effect of antireflux operation on Barrett's mucosa
186. Histological and anatomic changes in Barrett's esophagus after antireflux surgery
187. Barrett's esophagus: Does an antireflux procedure reduce the need for endoscopic surveillance?
188. Fundoplication provides effective and durable symptom relief in patients with Barrett's esophagus
189. Laparoscopic antireflux surgery in the treatment of gastroesophageal reflux in patients with Barrett's esophagus
190. Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus: Clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation
191. Regression of columnar esophageal (Barrett's) epithelium after anti-reflux surgery
192. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. Follow-up of a randomized controlled trial
193. Laser-induced transient regression of Barrett's epithelium
194. Repeat laser therapy of recurrent Barrett's epithelium: Success with anacidity
195. Restoration of squamous mucosa after ablation of Barrett's epithelium
196. Photothermal laser ablation of Barrett's oesophagus: Endoscopic and histological evidence of squamous reepithelialization
197. Treatment of Barrett's esophagus by endoscopic laser ablation and antireflux surgery
198. Endoscopic laser ablation of nondysplastic Barrett's epithelium: Is it worthwhile?
199. Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: A multicenter study
200. Pathologic documentation of complete elimination of Barrett's metaplasia following endoscopic multipolar electrocoagulation therapy
201. Antireflux surgery followed by bipolar electrocoagulation in the treatment of Barrett's esophagus
202. Successful reversal of Barrett's esophagus with multipolar electrocoagulation despite inadequate acid suppression
203. Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus
204. Complete regression of Barrett's esophagus with heat probe thermocoagulation: Mid-term results
205. Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett's esophagus
206. High power setting argon plasma coagulation for the eradication of Barrett's esophagus
207. Ablation of Barrett's epithelium by endoscopic encloscopic argon plasma coagulation in combination with high-dose omeprazole
208. The efficacy and safety of argon plasma coagulation therapy in Barrett's esophagus
209. Restoration of normal squamous lining in Barrett's esophagus by argon beam plasma coagulation
210. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: Immediate and mid term results
211. Laser and multipolar electrocoagulation of early Barrett's adenocarcinoma: Long-term follow-up
212. KTP laser destruction of dysplasia and early cancer in columnar-line Barrett's esophagus
213. Photodynamic therapy for Barrett's esophagus: Follow-up in 100 patients
214. Photodynamic therapy for Barrett's esophagus: Clinical update
215. A multicenter, partially blinded, randomized study of the efficacy of photodynamic therapy (PDT) using porfimer sodium for the ablation of high-grade dysplasia in Barrett's esophagus: Results of 6-month follow-up
216. Photodynamic ablation of high-grade dysplasia in Barrett's esophagus by means of 5-aminolevulinic acid
217. Photodynamic therapy for dysplastic Barrett's oesophagus: A prospective, double blind, randomised, placebo controlled trial
218. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy
219. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus
220. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus
221. Barrett's esophagus: An overrated cancer risk factor
222. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus
223. Biomarker studies in reversed Barrett's esophagus
224. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer
225. Barrett's-related esophageal adenocarcinoma: Is chemoprevention a potential option?